Latest news

On January 30, LynxCare had the honor of participating in Dedalus's annual D4Evolution conference in Paris, themed "Innovons et accélérons ensemble la e-santé" ("Let's Innovate and Accelerate E-Health Together"). This event brought together a vibrant community of clients, partners, and experts to discuss the future of digital health.

We are thrilled to announce our partnership with Dedalus, transforming Real-World Data access in Europe. By combining LynxCare’s disease-specific Natural Language Processing capabilities and Dedalus’ healthcare expertise, we're set to facilitate the access and curating of fresh clinical data directly from the hospital information system. This collaboration empowers healthcare institutions and life sciences companies with accurate patient insights for more informed clinical decisions and research.

We successfully completed a pilot project in mental health in collaboration with Obasi, and supported by Johnson & Johnson.

We are proud to share that we have been recognized as one of the World's Best Digital Health Companies by Newsweek and Statista!

As Heart Failure Awareness Week comes to a close, we wanted to take a moment to reflect on the insights shared throughout the week. We've delved into various aspects of heart failure management, from the promise of AI-NLP technology to bridging the gaps in heart failure research.

Artificial Intelligence is reshaping healthcare and revolutionizing how machines comprehend and generate human-like text, from drug discovery to virtual doctors, the potential of applying AI to the field of health seems endless. At LynxCare, AI plays a pivotal role in extracting insights from clinical documents that contain information in unstructured form. Our solution leverages Natural Language Processing, to process, transform, harmonize, standardize, and analyze millions of clinical documents into precise, accessible, and collaborative resources.

LynxCare is excited to announce the appointment of Laurent van Lerberghe, former Chief Strategy Officer at Sanofi, as Investor and Board Advisor. LynxCare is a scale-up company in Clinical Artificial Intelligence part of the CB Insights Global Digital Health 150, supported by renowned VC investors MTIP (CH), Elaia (FR), B2Ventures (CH-DE) and Heran partners (BE).

We are proud to share that we have successfully renewed our ISO 27001 and NEN 7510 certifications. These certifications are not just badges, but a reflection of our commitment to maintaining the highest information security standards in healthcare!

We discuss the potential of the abundant RWD for lung cancer presenting an invaluable resource when translated into RWE. While clinical trials are essential, they may not fully represent the real-world patient population. RWE complements clinical trial evidence by providing insights on treatment outcomes in broader, unselected patient groups, helping inform reimbursement decisions and ensuring access to innovative therapies.